The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://mariahcehw214302.buscawiki.com/1993345/retatrutide_vs_tirzepatide_a_comparative_analysis